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Unmet Needs of Clopidogrel in Acute Myocardial Infarction Compared with Unstable
Angina After 1 Month Administration
Jae Hyoung Park, Do-Sun Lim
Korea University Anam Hospital, Seoul, Korea, Republic of
Background: Clopidogrel resistance is more important in acute myocardial infarction
(AMI). We investigated high on-treatment platelet reactivity (HTPR) in acute cor-
onary syndrome (ACS).
Methods: Forty-six ACS patients undergoing percutaneous coronary intervention
(PCI) were screened with CYP 2C19 *2, *3 loss-of-function (LOF) polymorphism
and VerifyNow P2y12 assay at least 24 hours after clopidogrel 600mg loading,
deﬁning high on-treatment platelet reactivity (HTPR) as platelet reaction unit
(PRU)>230. According to genotyping and VerifyNow, we decided on anti-platelet
agents. Those with homozygous LOF allele and HTPR, we switched clopidogrel over
to prasugrel (10mg/day) (Group 1). And, those with normal genotyping (*1*1) and
normal platelet function (PRU<230), we maintained clopidogrel (75mg/day) (Group
4). Those with heterozygous LOF allele and HTPR, homozygous LOF allele and
normal platelet function, and normal genotyping and HTPR were randomized to
prasugrel (10mg/day) (Group 2) or clopidogrel (75mg/day) (Group 3). We checked
VerifyNow again 1 month later. Among clopidogrel group (Group 3 and 4), we
compared PRU between AMI (N¼16) and unstable angina (UA) (N¼9).
Results: After 1 month, among clopidogrel group, PRU value decreased less in AMI
than UA. (PRU 19190 to 17670 vs. 20455 to 14183; p (of D) ¼ 0.034). And,
there were decreases of HTPR patients in both groups (5/16 to 4/16 vs. 3/9 to 1/9).
Conclusions: Our study showed that there was unmet needs of clopidogrel in AMI
compared with UA about HTPR. And, there was additional decrease of PRU after 1
month clopidogrel administration compared with baseline loading status in ACS.CRT-126
Effective Platelet Inhibition with Triple Antiplatelet Regimen in High Risk PCI in
Patients with LV Dysfunction
Maddury Jyotsna,1 Janaswamy Vibhav Sri Narayana,2 K Tripathi Abhisheka1
1Nizam’s institute of medical sciences, secunderabad, India; 2Osmania Medical College,
Hyderabad, India
Background: Effective platelet inhibition is of paramount importance in patient
undergoing high risk PCI like LV dysfunction for prevention of early and late stent
related complications. We want to study the effect of triple antiplatelet (TAP) regimen
(Aspirin, Clopidogrel and Cilostazol) on platelet aggregation (PA) and long term
outcome in this subset of patients.
Methods: We retrospectively analyzed the details of patients with severe LV
dysfunction who underwent PCI in Jan 2010 to Dec 2010 in our unit, who were on
TAP regimen during ﬁrst month post PCI (after one month they were kept on DAP
agents for one year and thereafter on Aspirin only). We recorded their PA on 15th day
post PCI and their MACE (all cause death, MI, TLR, TVR, worsening of symptoms
of angina or HF, hospitalization due to HF) at 2 yrs and non-cardiac events (NCE)
(CVA, puncture site complications and renal dysfunction).
Results:Out of 215 eligible pts 177 (82.3%) were males (average age-54.9811.351
yrs). 139 (64.7%) were hypertensive, 96 (44.7%) were diabetic and 64 (29.8%) were
smokers. A total of 304 lesions were treated by PCI of which 55 (25.6%) were
multivessel. Transrdial PCI in 104 (48.4%) pts and DES in 149 (49.01%) lesions.
133 lesions in LAD, 68 in LCX-OM, 91 in RCA-PDA, 2 in LIMA to LAD, 6 in
SVG grafts and 4 ISR. Average stent size was 2.890.3mm and stent length was
19.45.7mm. On day 15, average PA was 40.3123.04%. Five patients were lost to
follow up and remaining 210 patients were followed up for 2 yrs. 166 (77.2%)
patients remained asymptomatic and 44 (22.8%) patients had one or more MACE
or non cardiac events. 40 patients had MACE, 8 patients had NCE which included
4 patients who also had MACE. 8 patients underwent TVR (1 stent thrombosis, 7
ISR) and 12 patients underwent non TVR (8 PCI, 4 CABG). Out of 11 patients
were hospitalized for heart failure, 9 had patent stent. 3 patients died, 2 with LVF
and 1 after CABG.
Conclusions: Effective platelet inhibition with TAP regimen in high risk patients
with LV dysfunction and CAD resulted in clinical beneﬁt in the form of low MACE
and NCE during long term follow up despite only nearly 50% of DES usage.
CRT-127
Patients Characteristics and Clinical Implications of Switching Antiplatelet Therapy
from Clopidogrel to Prasugrel or Ticagrelor
Michael J. Lipinski, Rebecca Torguson, Nevin C. Baker, Ricardo O. Escarcega, Fang Chen,
Lowell F. Satler, William O. Suddath, Augusto D. Pichard, Ron Waksman
MedStar Heart Institute, Washington, DC
Background: While 2nd generation anti-platelet therapy (Gen 2 APT), such as
Prasugrel and Ticagrelor, may have superior inhibition of platelet reactivity compared
with Clopidogrel, cost and compliance remains an issue for many patients. We sought
to assess whether Gen 2 APT use had an increased risk of stent thrombosis after being
switched from Clopidogrel from non-compliance.
Methods: We included patients from July 2009 until present who underwent PCI
with stent placement and followed clinical events following hospitalization. We then
obtained clinical follow-up on patients based on the anti-platelet medication on
admission and discharge to assess for a switch in the APT prescribed.
Results: We included 6,888 patients in our study (patient characteristics in Table 1).
Patients switched from clopidogrel to a Gen 2 APT were more likely to be admitted
for an acute myocardial infarction (64% vs 33% in the other groups, p<0.001). At 30
days and 6 months, there were no signiﬁcant differences in stent thrombosis between
the groups (all groups <1%). However, patients that were switched from clopidogrel to
a Gen 2 APT had a greater incidence of target vessel revascularization at 6 months
compared with patients that stayed on clopidogrel or that were switched from a Gen 2
APT to clopidogrel (12.6% vs 3.9% vs 5.4% respectively, p<0.001), suggesting that
patients switched to Gen 2 APT may represent a higher risk patient subset.
